Tech entrepreneur and longevity enthusiast Bryan Johnson recently revealed he is seriously considering shutting down or selling Blueprint, the anti-aging wellness company he founded. In a candid interview with Wired, he described the business as a “pain-in-the‑ass company”, stating, “Honestly, I am so close to either shutting it down or selling it. I don’t need the money…”
🔍 1. Why Blueprint Is Becoming a Burden
Johnson initially launched Blueprint to share his personal “Project Blueprint” longevity protocol and supplement stack. The business offers products like a ₹4,700 “longevity mix” drink and a ₹3,600 mushroom-based coffee replacement called “Super Shrooms,” but managing the operation has increasingly conflicted with his broader philosophical mission revolving around his new ideology, “Don’t Die”
🧠 2. Conflict With Vision and Credibility
Johnson shared that continuing the business negatively impacts his credibility within the philosophical and longevity communities. He feels that being seen as a commercial vendor undermines his message and dedication to the anti-aging cause. His business public profile now distracts from his main philosophical pursuits
💸 3. Financial Strain vs. Independence
Although not in immediate financial collapse, Blueprint has reportedly missed its breakeven estimates, sometimes losing over $1 million per month according to internal documents. Johnson maintains the company isn’t in crisis—stating it has had both profitable and loss months—but the uncertainty coupled with the operational burden reinforces his desire to exit
🚀 4. The Pivot to “Don’t Die”
In March 2025, Johnson launched “Don’t Die”, a philosophical movement advocating radical life extension beyond business or commerce. He believes Blueprint distracts from that mission and may hinder the credibility he needs to grow the movement’s influence
🌐 5. A Turning Point for Longevity Investing
Bryan’s exit from Blueprint marks a meaningful shift in the longevity sector. Analysts and investors view his departure as emblematic of how the future of the industry may move away from personality-driven ventures to more clinical, rigorously validated startups. The longevity investment landscape is shifting toward companies with scientific foundations, peer-reviewed research, and excess smaller-scale innovation taking center stage AInvest.
✅ Summary Table
| Key Theme | Details |
|---|---|
| Founder | Bryan Johnson, tech entrepreneur and longevity advocate |
| Company | Blueprint – supplements & wellness products |
| Announced Plans | Considering shutdown or sale |
| Reason | Business conflicts with philosophical vision, loss of credibility |
| Financial Context | Mixed profits, operational burden, possible losses |
| Broader Impact | Signals shift in longevity sector to science-driven, investor-backed ventures |
